|
1
|
Kleihues P, Louis DN, Scheithauer BW,
Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO
classification of tumors of the nervous system. J Neuropathol Exp
Neurol. 61:215–225; discussion 226-229. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiffer D: Classification and biology of
astrocytic gliomas. Forum (Genova). 8:244–255. 1998.PubMed/NCBI
|
|
3
|
Kleihues P, Soylemezoglu F, Schauble B,
Scheithauer BW and Burger PC: Histopathology, classification, and
grading of gliomas. Glia. 15:211–221. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wiestler OD and Wolf HK: Revised WHO
classification and new developments in diagnosis of central nervous
system tumors. Pathologe. 16:245–255. 1995.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kleihues P and Ohgaki H: Primary and
secondary glioblastomas: From concept to clinical diagnosis. Neuro
Oncol. 1:44–51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Durmaz R, Erken S, Arslantas A, Atasoy MA,
Bal C and Tel E: Management of glioblastoma multiforme: With
special reference to recurrence. Clin Neurol Neurosurg. 99:117–123.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsu E, Keene D, Ventureyra E, Matzinger
MA, Jimenez C, Wang HS and Grimard L: Bone marrow metastasis in
astrocytic gliomata. J Neurooncol. 37:285–293. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jubelirer SJ: A review of the treatment
and survival rates of 138 patients with glioblastoma multiforme. W
V Med J. 92:186–190. 1996.PubMed/NCBI
|
|
10
|
Park CC, Hartmann C, Folkerth R, Folkerth
R, Loeffler JS, Wen PY, Fine HA, Black PM, Shafman T and Louis DN:
Systemic metastasis in glioblastoma may represent the emergence of
neoplastic subclones. J Neuropathol Exp Neurol. 59:1044–1050. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scott JN, Rewcastle NB, Brasher PM, Fulton
D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG and Forsyth
P: Long-term glioblastoma multiforme survivors: A population-based
study. Can J Neurol Sci. 25:197–201. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Burton EC, Lamborn KR, Feuerstein BG,
Prados M, Scott J, Forsyth P, Passe S, Jenkins RB and Aldape KD:
Genetic aberrations defined by comparative genomic hybridization
distinguish long-term from typical survivors of glioblastoma.
Cancer Res. 62:6205–6210. 2002.PubMed/NCBI
|
|
13
|
Krex D, Klink B, Hartmann C, von Deimling
A, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger
G, et al: Long-term survival with glioblastoma multiforme. Brain.
130:2596–2606. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bleeker FE, Molenaar RJ and Leenstra S:
Recent advances in the molecular understanding of glioblastoma. J
Neurooncol. 108:11–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Freemantle SJ, Portland HB, Ewings K,
Dmitrovsky F, DiPetrillo K, Spinella MJ and Dmitrovsky E:
Characterization and tissue-specific expression of human
GSK-3-binding proteins FRAT1 and FRAT2. Gene. 291:17–27. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yost C, Farr GH III, Pierce SB, Ferkey DM,
Chen MM and Kimelman D: GBP, an inhibitor of GSK-3, is implicated
in Xenopus development and oncogenesis. Cell. 93:1031–1041. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan Y, Yang Z, Miao X, Li D, Liu Z and
Zou Q: The clinical significance of FRAT1 and ABCG2 expression in
pancreatic ductal adenocarcinoma. Tumour Biol. 36:9961–9968. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jonkers J, van Amerongen R, van der Valk
M, Robanus-Maandag E, Molenaar M, Destrée O and Berns A: In vivo
analysis of Frat1 deficiency suggests compensatory activity of
Frat3. Mech Dev. 88:183–194. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saitoh T, Mine T and Katoh M: Molecular
cloning and expression of proto-oncogene FRAT1 in human cancer. Int
J Oncol. 20:785–789. 2002.PubMed/NCBI
|
|
22
|
Jonkers J, Korswagen HC, Acton D, Breuer M
and Berns A: Activation of a novel proto-oncogene, Frat1,
contributes to progression of mouse T-cell lymphomas. EMBO J.
16:441–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jonkers J, Weening JJ, van der Valk M, van
der Valk M, Bobeldijk R and Berns A: Overexpression of Frat1 in
transgenic mice leads to glomerulosclerosis and nephrotic syndrome,
and provides direct evidence for the involvement of Frat1 in
lymphoma progression. Oncogene. 18:5982–5990. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H,
Zhou C, Zhang G, Quan L, Bai J and Xu N: Tissue microarray analysis
of human FRAT1 expression and its correlation with the subcellular
localisation of beta-catenin in ovarian tumours. Br J Cancer.
94:686–691. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Y, Han Y, Zheng R, Yu JH, Miao Y,
Wang L and Wang EH: Expression of Frat1 correlates with expression
of β-catenin and is associated with a poor clinical outcome in
human SCC and AC. Tumour Biol. 33:1437–1444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan
CF, Dong XJ, Dai SD and Wang EH: Overexpression of Frat1 correlates
with malignant phenotype and advanced stage in human non-small cell
lung cancer. Virchows Arch. 459:255–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan WH, Du FJ, Liu XJ and Chen N:
Knockdown of FRAT1 inhibits hypoxia-induced
epithelial-to-mesenchymal transition via suppression of the
Wnt/β-catenin pathway in hepatocellular carcinoma cells. Oncol Rep.
36:2999–3004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo G, Kuai D, Cai S, Xue N, Liu Y, Hao J,
Fan Y, Jin J, Mao X, Liu B, et al: Knockdown of FRAT1 expression by
RNA interference inhibits human glioblastoma cell growth, migration
and invasion. PLoS One. 8:e612062013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gao YF, Mao XY, Zhu T, Mao CX, Liu ZX,
Wang ZB, Li L, Li X, Yin JY, Zhang W, et al: COL3A1 and SNAP91:
Novel glioblastoma markers with diagnostic and prognostic value.
Oncotarget. 7:70494–70503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Duarte CW, Willey CD, Zhi D, Cui X, Harris
JJ, Vaughan LK, Mehta T, McCubrey RO, Khodarev NN, Weichselbaum RR
and Gillespie GY: Expression signature of IFN/STAT1 signaling genes
predicts poor survival outcome in glioblastoma multiforme in a
subtype-specific manner. PLoS One. 7:e296532012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng
Z, Zhu G, Qi J, Ma H, Nian H and Wang Y: RNA-seq analyses of
multiple meristems of soybean: Novel and alternative transcripts,
evolutionary and functional implications. BMC Plant Biol.
14:1692014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu J, Mao X, Cai T, Luo J and Wei L: KOBAS
server: A web-based platform for automated annotation and pathway
identification. Nucleic Acids Res. 34:W720–W724. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sherman BT, Huang da W, Tan Q, Guo Y, Bour
S, Liu D, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID
Knowledgebase: A gene-centered database integrating heterogeneous
gene annotation resources to facilitate high-throughput gene
functional analysis. BMC Bioinformatics. 8:4262007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kramer A, Green J, Pollard J Jr and
Tugendreich S: Causal analysis approaches in ingenuity pathway
analysis. Bioinformatics. 30:523–530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Culbert AA, Brown MJ, Frame S, Hagen T,
Cross DA, Bax B and Reith AD: GSK-3 inhibition by adenoviral FRAT1
overexpression is neuroprotective and induces Tau dephosphorylation
and beta-catenin stabilisation without elevation of glycogen
synthase activity. FEBS Lett. 507:288–294. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hagen T, Cross DA, Culbert AA, West A,
Frame S, Morrice N and Reith AD: FRAT1, a substrate-specific
regulator of glycogen synthase kinase-3 activity, is a cellular
substrate of protein kinase A. J Biol Chem. 281:35021–35029. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li L, Yuan H, Weaver CD, Mao J, Farr GH
III, Sussman DJ, Jonkers J, Kimelman D and Wu D: Axin and Frat1
interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated
regulation of LEF-1. EMBO J. 18:4233–4240. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thomas GM, Frame S, Goedert M, Nathke I,
Polakis P and Cohen P: A GSK3-binding peptide from FRAT1
selectively inhibits the GSK3-catalysed phosphorylation of axin and
beta-catenin. FEBS Lett. 458:247–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jamieson C, Sharma M and Henderson BR: Wnt
signaling from membrane to nucleus: β-catenin caught in a loop. Int
J Biochem Cell Biol. 44:847–850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yong Z, Yu JH, Lin XY, Miao Y, Han Y, Fan
CF, Dong XJ, Dai SD and Wang EH: Overexpression of Frat1 correlates
with malignant phenotype and advanced stage in human non-small cell
lung cancer. Virchows Archiv. 459:255–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo G, Liu B, Zhong C, Zhang X, Mao X,
Wang P, Jiang X, Huo J, Jin J, Liu X and Chen X: FRAT1 expression
and its correlation with pathologic grade, proliferation, and
apoptosis in human astrocytomas. Med Oncol. 28:1–6. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ihle JN: STATs: Signal transducers and
activators of transcription. Cell. 84:331–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Matikainen S, Sareneva T, Ronni T,
Lehtonen A, Koskinen PJ and Julkunen I: Interferon-alpha activates
multiple STAT proteins and upregulates proliferation-associated
IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood.
93:1980–1991. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kharma B, Baba T, Matsumura N, Kang HS,
Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe
Y, et al: STAT1 drives tumor progression in serous papillary
endometrial cancer. Cancer Res. 74:6519–6530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lilly M and Kraft A: Enforced expression
of the Mr 33,000 Pim-1 kinase enhances factor-independent survival
and inhibits apoptosis in murine myeloid cells. Cancer Res.
57:5348–5355. 1997.PubMed/NCBI
|
|
49
|
Moroy T, Grzeschiczek A, Petzold S and
Hartmann KU: Expression of a Pim-1 transgene accelerates
lymphoproliferation and inhibits apoptosis in lpr/lpr mice. Proc
Natl Acad Sci USA. 90:10734–10738. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Meng D, Chen Y, Yun D, Zhao Y, Wang J, Xu
T, Li X, Wang Y, Yuan L, Sun R, et al: High expression of N-myc
(and STAT) interactor predicts poor prognosis and promotes tumor
growth in human glioblastoma. Oncotarget. 6:4901–4919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gouilleux-Gruart V, Gouilleux F, Desaint
C, Claisse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Fourt
I, Dreyfus F, Groner B and Prin L: STAT-related transcription
factors are constitutively activated in peripheral blood cells from
acute leukemia patients. Blood. 87:1692–1697. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Grandis JR, Drenning SD, Chakraborty A,
Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but
not Stat1 activation for epidermal growth factor receptor-mediated
cell growth In vitro. J Clin Invest. 102:1385–1392. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gouilleux-Gruart V, Debierre-Grockiego F,
Gouilleux F, Capiod JC, Claisse JF, Delobel J and Prin L: Activated
Stat related transcription factors in acute leukemia. Leuk
Lymphoma. 28:83–88. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bromberg JF: Activation of STAT proteins
and growth control. Bioessays. 23:161–169. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Catlett-Falcone R, Dalton WS and Jove R:
STAT proteins as novel targets for cancer therapy. Signal
transducer an activator of transcription. Curr Opin Oncol.
11:490–496. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hackenmiller R, Kim J, Feldman RA and
Simon MC: Abnormal Stat activation, hematopoietic homeostasis, and
innate immunity in c-fes-/- mice. Immunity. 13:397–407. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Delwar ZM, Kuo Y, Wen YH, Rennie PS and
Jia W: Oncolytic virotherapy blockade by microglia and macrophages
requires STAT1/3. Cancer Res. 78:718–730. 2018. View Article : Google Scholar : PubMed/NCBI
|
